Metabolite Identification (Met ID) for ADC
Our Metabolite Identification service for Antibody-Drug Conjugates (ADCs) applies immuno-capture and HRMS to detect payload-containing catabolites, linker cleavages, and biotransformations in biological samples. This targeted assay quantifies free payloads, metabolites, and intact conjugates, assessing stability and off-target risks. Essential for ADC development, it informs payload design and pharmacokinetics, ensuring compli…
Metabolite Identification (Met ID) for ADC
Receive your quote directly from the manufacturer.
ADCs in vivo instability can release free drugs or metabolites, impacting efficacy and toxicity. Our platform uses LC-HRMS for profiling payload species, employing dedicated software to identify catabolites from in vitro and in vivo matrices like plasma and tumors. This reveals major metabolic pathways, including deconjugation and payload modifications. Customizable for cleavable and non-cleavable linkers, the service provides structural data, DAR changes, and quantitative profiles.
Key features or benefits:
- ADC-specific workflows: Immuno-capture enrichment followed by HRMS analysis.
- Comprehensive profiling: Detects payloads, metabolites, and conjugate forms.
- Rapid turnaround: ~2-3 weeks
- Expert insights: Includes stability evaluations and regulatory reporting.
Relevant applications:
- Drug discovery: Optimizing linker-payload stability.
- Preclinical ADME: Identifying catabolites in hepatic and tumor fractions.
- Toxicity screening: Assessing free payload release and metabolites.
